AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
suramin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2966 | 145-63-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.27 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.54 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.01 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1200 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P01CX02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS Other agents against leishmaniasis and trypanosomiasis |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000969 | Antinematodal Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D014344 | Trypanocidal Agents |
| CHEBI has role | CHEBI:35444 | antinematodal drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:36335 | trypanocidal drug |
| CHEBI has role | CHEBI:37700 | EC 2.7.11.13 (protein kinase C) inhibitor |
| CHEBI has role | CHEBI:38999 | GABA-gated chloride channel antagonist |
| CHEBI has role | CHEBI:48422 | angiogenesis inhibitor |
| CHEBI has role | CHEBI:65259 | GABA antagonist |
| CHEBI has role | CHEBI:67114 | ryanodine receptor agonist |
| CHEBI has role | CHEBI:68494 | apoptosis inhibitor |
| CHEBI has role | CHEBI:70868 | antileishmanial agent |
| CHEBI has role | CHEBI:91079 | purinergic receptor P2 antagonist |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
P01CX Other agents against leishmaniasis and trypanosomiasis 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| African trypanosomiasis | indication | 27031003 | DOID:10112 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.86 | acidic |
| pKa2 | 9.47 | acidic |
| pKa3 | 12.22 | acidic |
| pKa4 | 12.82 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 | Enzyme | Ki | 6.58 | CHEMBL | |||||
| Tyrosine-protein phosphatase non-receptor type 1 | Enzyme | IC50 | 5.85 | CHEMBL | |||||
| P2X purinoceptor 1 | Ion channel | IC50 | 5.37 | CHEMBL | |||||
| NAD-dependent protein deacetylase sirtuin-1 | Enzyme | IC50 | 6.52 | CHEMBL | |||||
| P2Y purinoceptor 6 | GPCR | ANTAGONIST | Kb | 4 | IUPHAR | ||||
| P2Y purinoceptor 1 | GPCR | ANTAGONIST | Ki | 5.30 | IUPHAR | ||||
| NAD-dependent protein deacetylase sirtuin-2 | Enzyme | IC50 | 5.96 | CHEMBL | |||||
| P2Y purinoceptor 2 | GPCR | ANTAGONIST | IC50 | 4.30 | IUPHAR | ||||
| P2Y purinoceptor 11 | GPCR | ANTAGONIST | IC50 | 6 | IUPHAR | ||||
| Protein arginine N-methyltransferase 1 | Enzyme | IC50 | 5.27 | CHEMBL | |||||
| P2Y purinoceptor 13 | GPCR | ANTAGONIST | IC50 | 5.60 | IUPHAR | ||||
| DNA-dependent protein kinase catalytic subunit | Kinase | IC50 | 5.77 | CHEMBL | |||||
| P2X purinoceptor 4 | Ion channel | Ki | 6.75 | PDSP | |||||
| Protein kinase C (PKC) | Kinase | IC50 | 4.54 | CHEMBL | |||||
| P2X purinoceptor 3 | Ion channel | Ki | 5.96 | PDSP | |||||
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Enzyme | IC50 | 4.85 | CHEMBL | |||||
| Heparanase | Enzyme | IC50 | 4.58 | CHEMBL | |||||
| Signal transducer and activator of transcription 1-alpha/beta | Transcription factor | IC50 | 5.04 | CHEMBL | |||||
| Signal transducer and activator of transcription 5A | Transcription factor | IC50 | 5.03 | CHEMBL | |||||
| Signal transducer and activator of transcription 5B | Transcription factor | IC50 | 4.98 | CHEMBL | |||||
| P2X purinoceptor 7 | Ion channel | IC50 | 4.48 | CHEMBL | |||||
| Pyruvate kinase PKLR | Enzyme | Ki | 5.96 | CHEMBL | |||||
| Pyruvate kinase PKM | Enzyme | Ki | 5 | CHEMBL | |||||
| Protein argonaute-2 | Enzyme | IC50 | 6.16 | CHEMBL | |||||
| Reverse transcriptase/RNaseH | Enzyme | IC50 | 5.03 | CHEMBL | |||||
| RmtA | Enzyme | IC50 | 5.23 | CHEMBL | |||||
| ATP-dependent 6-phosphofructokinase | Kinase | IC50 | 5.52 | CHEMBL | |||||
| Nucleoside triphosphate diphosphohydrolase 3 | Enzyme | Ki | 4.90 | CHEMBL | |||||
| Ectonucleoside triphosphate diphosphohydrolase 2 | Enzyme | Ki | 4.18 | CHEMBL | |||||
| P2X purinoceptor 3 | Ion channel | ANTAGONIST | IC50 | 5.52 | IUPHAR | ||||
| P2X purinoceptor 2 | Ion channel | ANTAGONIST | IC50 | 4.98 | IUPHAR | ||||
| P2X purinoceptor 1 | Ion channel | ANTAGONIST | IC50 | 6 | IUPHAR | ||||
| P2X purinoceptor 5 | Ion channel | ANTAGONIST | IC50 | 5.40 | IUPHAR | ||||
| Replicase polyprotein 1ab | Enzyme | IC50 | 6.58 | CHEMBL | |||||
| Genome polyprotein | Polyprotein | EC50 | 5.71 | CHEMBL | |||||
| NAD-dependent protein deacetylase | Enzyme | IC50 | 5.16 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| N0000167387 | NUI |
| D00808 | KEGG_DRUG |
| C0038880 | UMLSCUI |
| CHEBI:45906 | CHEBI |
| SVR | PDB_CHEM_ID |
| CHEMBL265502 | ChEMBL_ID |
| CHEMBL413376 | ChEMBL_ID |
| D013498 | MESH_DESCRIPTOR_UI |
| DB04786 | DRUGBANK_ID |
| 1728 | IUPHAR_LIGAND_ID |
| 129-46-4 | SECONDARY_CAS_RN |
| 6032D45BEM | UNII |
| 5361 | PUBCHEM_CID |
| 10256 | RXNORM |
| 002969 | NDDF |
| 004968 | NDDF |
| 67928003 | SNOMEDCT_US |
| 714082002 | SNOMEDCT_US |
| 714537005 | SNOMEDCT_US |
| 2899 | INN_ID |
| 6032D45BEM | INXIGHT DRUGS |
Pharmaceutical products:
None